ClinicalTrials.gg
CompletedNCT02369874EAGLEUpdated Feb 10, 2021Results posted

Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer

A Phase 3 interventional study of MEDI4736 and MEDI4736 + Tremelimumab in Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN, sponsored by AstraZeneca. Completed at 169 sites in 24 countries. Open to participants aged 18 Years to 96 Years. Per ClinicalTrials.gov, last updated 2021-02-10.

Primary conditionHead and Neck NeoplasmsRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Head and Neck Neoplasms
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's title name Head and Neck Neoplasms.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
736
Allocation
Randomized
Ages
18 Years to 96 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies in Head and Neck Neoplasms by AstraZeneca — 1 open to participants now, 3 under way, 1 of them phase 3. Head and Neck Neoplasms · AstraZeneca.

Enrollment
Largest of 15
736 · median 47
Started
2015
with 1 other
Phase 3
2 of 17
none open now
Registered
12th of 17
by date

Among the 17 studies in Head and Neck Neoplasms by AstraZeneca, this one has the largest enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2015, is one of 2 in phase 3, and was the 12th registered.

Head and Neck Neoplasms

2,714 studies on the registry are indexed under Head and Neck Neoplasms; 596 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

1 of the 17 studies in Head and Neck Neoplasms by AstraZeneca is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 453 Head and Neck Neoplasms studies recruiting now, 345 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 21 take children under 18; 27 take healthy volunteers.

This study: 18 Years to 96 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Head and Neck Neoplasms by AstraZeneca, or all of them as a file.
02

Study summary

This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus SoC therapy in the target patient population.

Read the detailed description

This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus SoC therapy in the target patient population.

The main objectives of the study are to:

  • assess the efficacy of MEDI4736 + tremelimumab combination therapy versus SoC in patients with squamous cell carcinoma of the head and neck (SCCHN), in terms of overall survival (OS), regardless of PDL-1 status
  • assess the efficacy of MEDI4736 monotherapy versus SOC in patients with SCCHN, in terms of OS, regardless of PDL-1 status

Patients will undergo a screening assessment on their tumor tissue sample to determine PD-L1 expression per a pre-specified cut-off level. Patients with ≥25% of tumor cells with membrane staining will be considered PD-L1 positive while those with 0% to 24% of tumor cells with membrane staining will be considered PD-L1 negative. Based on the underlying PD-L1 status, patients will be randomized in a 1:1:1 ratio to receive treatment with MEDI4736 monotherapy, MEDI4736 + tremelimumab combination therapy, or SoC therapy. Patients who discontinue treatment in 1 treatment group may not switch to treatment in a different group.

Stratification factors include PD-L1 status, human papillomavirus status, (in patients with oropharyngeal cancer only), and smoking status.

Tumor assessments will be performed every 8 weeks until objective tumor response by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).

03

Conditions studied

  • Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN

Browse trials for

Keywords

  • Head and Neck cancer; MEDI4736; Tremelimumab
04

In context

Head and Neck Neoplasms Reclassified

2,714 studies on the registry are indexed under Head and Neck Neoplasms; 596 are open to participants now.

This study's enrollment of 736 is above the median of 46 across 2,033 interventional studies indexed under Head and Neck Neoplasms.

Browse Head and Neck Neoplasms studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Compared within Head and Neck Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 96 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: - Age ≥18 years; - Written obtained from the patient/legal representative; - or cytologically confirmed recurrent or SCCHN; - Tumor progression or recurrence during or after only one palliative systemic treatment regimen for recurrent or metastatic disease that must have contained a platinum agent OR progression within 6 months of the last dose of platinum given as part of multimodality therapy with curative intent; - Confirmed -positive or -negative SCCHN by the Ventana PD-L1 SP263 IHC assay; - WHO/ (ECOG) performance status of 0 or 1; At least 1 , - Not previously irradiated; - No prior exposure to immune-mediated therapy; - Adequate organ and marrow function; Evidence of status or negative urinary or serum pregnancy test for female pre-menopausal patients. Exclusion Criteria: - Histologically or cytologically confirmed squamous cell carcinoma of any other primary anatomic location in the head and neck; - Received more than 1 palliative systemic regimen for recurrent or metastatic disease; -Any concurrent chemotherapy, Product, biologic, or hormonal therapy for cancer treatment; - Receipt of any investigational anticancer therapy within 28 days or 5 half-lives; - Receipt of last dose of an approved (marketed) anticancer therapy (chemotherapy, targeted therapy, biologic therapy, mAbs, etc) within 21 days prior to the first dose of study treatment; - Major surgical procedure within 28 days prior to the first dose of Investigational Product; - Any unresolved toxicity Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criterion; - Current or prior use of medication within 14 days before the first dose of their assigned Investigational Product; - History of allogeneic organ transplantation; - Active or prior documented or inflammatory disorders; - Uncontrolled intercurrent illness; - Patients with a history of , spinal cord compression, or ; - Mean corrected for heart rate (QTc) ≥470 ms calculated from 3 (ECGs) using Fridericia's Correction; - History of active primary immunodeficiency; - Active tuberculosis; - Active infection including , or (HIV); - Receipt of live, attenuated vaccine within 30 days prior to the first dose of Investigational Product; - Pregnant or breast-feeding female patients; - Known allergy or to Investigational Product

Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
736 participants (actual)

Study arms

  • Experimental
    MEDI4736

    MEDI4736 monotherapy

    Drug: MEDI4736

  • Experimental
    MEDI4736 + Tremelimumab

    MEDI4736 + tremelimumab combination therapy

    Drug: MEDI4736 + Tremelimumab

  • Active comparator
    Standard of Care

    Standard of Care

    Drug: Standard of Care

Interventions

  • MEDI4736 Monotherapy

  • DrugMEDI4736 + Tremelimumab

    Drug pages: Durvalumab · Tremelimumab

    MEDI4736 + Tremelimumab combination therapy

  • DrugStandard of Care

    Standard of Care

07

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from the date of randomization until death due to any cause. OS was analyzed for the full analysis set, regardless of programmed death-ligand 1 (PD-L1) status.

    Time frame: September 2015 to September 2018 (36 months)

Secondary outcomes

  1. Overall Survival (OS) in PD-L1 Negative Participants

    OS is defined as the time from the date of randomization until death due to any cause. PD-L1 negative was defined as \<25% of tumor cells with membrane staining for PD-L1 at any intensity.

    Time frame: September 2015 to September 2018 (36 months)

  2. Overall Survival (OS) in PD-L1 Positive Participants

    OS is defined as the time from the date of randomization until death due to any cause. PD-L1 positive was defined as ≥25% of tumor cells with membrane staining for PD-L1 at any intensity.

    Time frame: September 2015 to September 2018 (36 months)

  3. Progression Free Survival (PFS)

    PFS was defined as the time from the date of randomization until the date of objective disease progression or death based on investigator assessments, according to response evaluation criteria in solid tumors 1.1 (RECIST1.1). Objective disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: September 2015 to September 2018 (36 months)

  4. Objective Response Rate (ORR)

    The percentage of participants who experienced an objective response (complete response \[CR\] or partial response \[PR\]), based on investigator assessments according to response evaluation criteria in solid tumors 1.1 (RECIST1.1). A CR was defined as the disappearance of all target lesions (TLs) since baseline. Any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10 mm. A PR was defined as at least a 30% decrease in the sum of the diameters of TLs, taking as reference the baseline sum of diameters.

    Time frame: Assessed at randomization and every 8 weeks thereafter

  5. Duration of Response (DoR)

    Median DoR, in months, based on investigator assessments, according to response evaluation criteria in solid tumors 1.1 (RECIST1.1). A complete response was defined as the disappearance of all target lesions (TLs) since baseline. Any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10 mm. A partial response was defined as at least a 30% decrease in the sum of the diameters of TLs, taking as reference the baseline sum of diameters.

    Time frame: September 2015 to September 2018 (36 months)

  6. Disease Control Rate (DCR)

    6 Months: The percentage of participants who had a best objective response of complete response (CR) or partial response (PR) in the first 6 months or had demonstrated stable disease (SD) for a minimum interval of 24 weeks following randomization. 12 Months: The percentage of participants who had a best objective response of CR or PR within 12 months or had demonstrated SD for a minimum interval of 48 weeks following randomization. Objective response was based on investigator assessments, according to response evaluation criteria in solid tumors 1.1 (RECIST1.1). A CR was defined as the disappearance of all target lesions (TLs) since baseline. Any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10 mm. A PR was defined as at least a 30% decrease in the sum of the diameters of TLs, taking as reference the baseline sum of diameters.

    Time frame: Baseline up to 6 months; baseline up to 12 months

  7. Percentage of Participants Alive and Progression Free (APF)

    APF is defined as the percentage of participants who are alive and progression free at 6 months and 12 months after randomization. Estimates of progression free survival were based on investigator assessments according to response evaluation criteria in solid tumors 1.1 (RECIST1.1). Objective disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: Baseline up to 6 months; baseline up to 12 months

  8. Percentage of Participants Alive

    Percentage of participants alive at 12, 18 and 24 months using a Kaplan Meier estimate.

    Time frame: 12, 18 and 24 months

  9. Progression Free Survival (PFS) in PD-L1 Negative Participants

    Number of participants with confirmed objective disease progression (PD) at the time of the participant's last evaluable response evaluation criteria in solid tumors 1.1 (RECIST1.1) assessment. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. PD-L1 negative was defined as \<25% of tumor cells with membrane staining for PD-L1 at any intensity.

    Time frame: September 2015 to September 2018 (36 months)

  10. Objective Response Rate (ORR) in PD-L1 Negative Participants

    The percentage of PD-L1 negative participants who experienced an objective response (complete response \[CR\] or partial response \[PR\]), based on investigator assessments according to response evaluation criteria in solid tumors 1.1 (RECIST1.1). A CR was defined as the disappearance of all target lesions (TLs) since baseline. Any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10 mm. A PR was defined as at least a 30% decrease in the sum of the diameters of TLs, taking as reference the baseline sum of diameters. PD-L1 negative was defined as \<25% of tumor cells with membrane staining for PD-L1 at any intensity.

    Time frame: September 2015 to September 2018 (36 months)

  11. Time to Deterioration in European Organisation for Research and Treatment of Cancer 30-item Core Quality of Life Questionnaire, Version 3 (EORTC QLQ-C30)

    The EORTC QLQ-C30 consists of 30 questions that can be combined to produce functional scales (e.g. physical), symptom scales (e.g. fatigue), and a global measure of health status. Each of the scales are measured from 0 to 100. Deterioration was defined as a 10-point decrease from baseline in a functioning or global health status/ quality of life score or a 10-point increase from baseline in a symptom score.

    Time frame: September 2015 to September 2018 (36 months)

  12. Time to Deterioration for European Organisation for Research and Treatment of Cancer 35-item Head and Neck Quality of Life Questionnaire (EORTC QLQ-H&N35)

    The EORTC QLQ-H\&N35 comprises of 35 questions to assess head and neck cancer symptoms (e.g. pain, swallowing). Deterioration was defined as a 10-point increase from baseline in the symptom score.

    Time frame: September 2015 to September 2018 (36 months)

  13. Number of Participants Reporting One or More Adverse Events (AE)

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. Inclusive of AEs and serious AEs.

    Time frame: First dose to last dose + 90 days or data cut off (up to 36 months)

08

Results

Posted Oct 3, 2019
Limitations and caveats
Multiple testing was performed for OS analysis in the intent-to-treat (ITT) population and OS analysis in the PD-L1 negative population for durvalumab + tremelimumab versus SoC only.

Participant flow

Participant flow — Overall Study
MilestoneDurvalumab + TremelimumabDurvalumabStandard of Care (SoC)
Started247240249
Received treatment246237240
Completed203183188
Not completed445761
Withdrew: Lost to follow-up222
Withdrew: Withdrawal by subject7927
Withdrew: Miscellaneous110
Withdrew: On treatment/off study344532

Outcome measures

PrimaryOverall Survival (OS)

OS is defined as the time from the date of randomization until death due to any cause. OS was analyzed for the full analysis set, regardless of programmed death-ligand 1 (PD-L1) status.

Time frame:
September 2015 to September 2018 (36 months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsDurvalumab + TremelimumabDurvalumabStandard of Care (SoC)
Overall Survival (OS)6.5 (5.5 to 8.2)7.6 (6.1 to 9.8)8.3 (7.3 to 9.2)
Statistical analysis
  • Durvalumab + Tremelimumab vs Standard of Care (SoC) · Log Rank · p = 0.7624 · Hazard ratio (hr): 1.04 · 95% CI 0.85 to 1.26
  • Durvalumab vs Standard of Care (SoC) · Log Rank · p = 0.1993 · Hazard ratio (hr): 0.88 · 95% CI 0.72 to 1.08
SecondaryOverall Survival (OS) in PD-L1 Negative Participants

OS is defined as the time from the date of randomization until death due to any cause. PD-L1 negative was defined as \<25% of tumor cells with membrane staining for PD-L1 at any intensity.

Time frame:
September 2015 to September 2018 (36 months)
Reported as:
Median · Months
Overall Survival (OS) in PD-L1 Negative Participants
MonthsDurvalumab + TremelimumabDurvalumabStandard of Care (SoC)
Overall Survival (OS) in PD-L1 Negative Participants7.8 (5.9 to 10.3)7.6 (6.2 to 9.5)8.0 (6.7 to 8.9)
Statistical analysis
  • Durvalumab + Tremelimumab vs Standard of Care (SoC) · Log Rank · p = 0.4590 · Hazard ratio (hr): 0.92 · 95% CI 0.73 to 1.17
  • Durvalumab + Tremelimumab vs Durvalumab · Hazard ratio (hr): 1.08 · 95% CI 0.85 to 1.36
SecondaryOverall Survival (OS) in PD-L1 Positive Participants

OS is defined as the time from the date of randomization until death due to any cause. PD-L1 positive was defined as ≥25% of tumor cells with membrane staining for PD-L1 at any intensity.

Time frame:
September 2015 to September 2018 (36 months)
Reported as:
Median · Months
Overall Survival (OS) in PD-L1 Positive Participants
MonthsDurvalumab + TremelimumabDurvalumabStandard of Care (SoC)
Overall Survival (OS) in PD-L1 Positive Participants4.8 (3.3 to 6.4)9.8 (4.3 to 14.1)9.0 (6.8 to 9.2)
Statistical analysis
  • Durvalumab vs Standard of Care (SoC) · Hazard ratio (hr): 0.93 · 95% CI 0.63 to 1.39
SecondaryProgression Free Survival (PFS)

PFS was defined as the time from the date of randomization until the date of objective disease progression or death based on investigator assessments, according to response evaluation criteria in solid tumors 1.1 (RECIST1.1). Objective disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
September 2015 to September 2018 (36 months)
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsDurvalumab + TremelimumabDurvalumabStandard of Care (SoC)
Progression Free Survival (PFS)2.0 (1.9 to 2.3)2.1 (1.9 to 3.0)3.7 (3.1 to 3.7)
Statistical analysis
  • Durvalumab + Tremelimumab vs Standard of Care (SoC) · Hazard ratio (hr): 1.09 · 95% CI 0.90 to 1.33
  • Durvalumab vs Standard of Care (SoC) · Hazard ratio (hr): 1.02 · 95% CI 0.84 to 1.25
SecondaryObjective Response Rate (ORR)

The percentage of participants who experienced an objective response (complete response \[CR\] or partial response \[PR\]), based on investigator assessments according to response evaluation criteria in solid tumors 1.1 (RECIST1.1). A CR was defined as the disappearance of all target lesions (TLs) since baseline. Any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10 mm. A PR was defined as at least a 30% decrease in the sum of the diameters of TLs, taking as reference the baseline sum of diameters.

Time frame:
Assessed at randomization and every 8 weeks thereafter
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR)
Percentage of participantsDurvalumab + TremelimumabDurvalumabStandard of Care (SoC)
Objective Response Rate (ORR)18.2 (13.6 to 23.6)17.9 (13.3 to 23.4)17.3 (12.8 to 22.5)
Statistical analysis
  • Durvalumab + Tremelimumab vs Standard of Care (SoC) · Odds ratio (or): 1.07 · 95% CI 0.67 to 1.70
  • Durvalumab vs Standard of Care (SoC) · Odds ratio (or): 1.05 · 95% CI 0.66 to 1.68
SecondaryDuration of Response (DoR)

Median DoR, in months, based on investigator assessments, according to response evaluation criteria in solid tumors 1.1 (RECIST1.1). A complete response was defined as the disappearance of all target lesions (TLs) since baseline. Any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10 mm. A partial response was defined as at least a 30% decrease in the sum of the diameters of TLs, taking as reference the baseline sum of diameters.

Time frame:
September 2015 to September 2018 (36 months)
Reported as:
Median · Months
Duration of Response (DoR)
MonthsDurvalumab + TremelimumabDurvalumabStandard of Care (SoC)
Duration of Response (DoR)7.4 (2.8 to NA)12.9 (5.6 to NA)3.7 (1.9 to 5.5)
SecondaryDisease Control Rate (DCR)

6 Months: The percentage of participants who had a best objective response of complete response (CR) or partial response (PR) in the first 6 months or had demonstrated stable disease (SD) for a minimum interval of 24 weeks following randomization. 12 Months: The percentage of participants who had a best objective response of CR or PR within 12 months or had demonstrated SD for a minimum interval of 48 weeks following randomization. Objective response was based on investigator assessments, according to response evaluation criteria in solid tumors 1.1 (RECIST1.1). A CR was defined as the disappearance of all target lesions (TLs) since baseline. Any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10 mm. A PR was defined as at least a 30% decrease in the sum of the diameters of TLs, taking as reference the baseline sum of diameters.

Time frame:
Baseline up to 6 months; baseline up to 12 months
Reported as:
Number · Percentage of participants
Disease Control Rate (DCR)
Percentage of participantsDurvalumab + TremelimumabDurvalumabStandard of Care (SoC)
6 Months25.124.224.9
12 Months20.618.818.9
Statistical analysis
  • Durvalumab + Tremelimumab vs Standard of Care (SoC) · Odds ratio (or): 1.01 · 95% CI 0.67 to 1.52
  • Durvalumab vs Standard of Care (SoC) · Odds ratio (or): 0.96 · 95% CI 0.64 to 1.46
  • Durvalumab + Tremelimumab vs Standard of Care (SoC) · Odds ratio (or): 1.12 · 95% CI 0.72 to 1.75
  • Durvalumab vs Standard of Care (SoC) · Odds ratio (or): 1.00 · 95% CI 0.63 to 1.57
SecondaryPercentage of Participants Alive and Progression Free (APF)

APF is defined as the percentage of participants who are alive and progression free at 6 months and 12 months after randomization. Estimates of progression free survival were based on investigator assessments according to response evaluation criteria in solid tumors 1.1 (RECIST1.1). Objective disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
Baseline up to 6 months; baseline up to 12 months
Reported as:
Number · Percentage of participants
Percentage of Participants Alive and Progression Free (APF)
Percentage of participantsDurvalumab + TremelimumabDurvalumabStandard of Care (SoC)
6 Months22.5 (17.4 to 28.0)25.1 (19.7 to 30.9)23.3 (17.8 to 29.3)
12 Months11.0 (7.4 to 15.5)14.4 (10.1 to 19.5)5.7 (2.8 to 10.2)
SecondaryPercentage of Participants Alive

Percentage of participants alive at 12, 18 and 24 months using a Kaplan Meier estimate.

Time frame:
12, 18 and 24 months
Reported as:
Number · Percentage of participants
Percentage of Participants Alive
Percentage of participantsDurvalumab + TremelimumabDurvalumabStandard of Care (SoC)
12 Months30.4 (24.7 to 36.3)37.0 (30.9 to 43.1)30.5 (24.7 to 36.4)
18 Months21.0 (15.9 to 26.5)25.4 (19.9 to 31.3)17.8 (13.1 to 23.2)
24 Months13.3 (8.9 to 18.6)18.4 (13.3 to 24.1)10.3 (5.7 to 16.5)
SecondaryProgression Free Survival (PFS) in PD-L1 Negative Participants

Number of participants with confirmed objective disease progression (PD) at the time of the participant's last evaluable response evaluation criteria in solid tumors 1.1 (RECIST1.1) assessment. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. PD-L1 negative was defined as \<25% of tumor cells with membrane staining for PD-L1 at any intensity.

Time frame:
September 2015 to September 2018 (36 months)
Reported as:
Count of participants · Participants
Progression Free Survival (PFS) in PD-L1 Negative Participants
ParticipantsDurvalumab + TremelimumabDurvalumabStandard of Care (SoC)
Progression Free Survival (PFS) in PD-L1 Negative Participants154151144
Statistical analysis
  • Durvalumab + Tremelimumab vs Durvalumab · Hazard ratio (hr): 0.96 · 95% CI 0.76 to 1.21
SecondaryObjective Response Rate (ORR) in PD-L1 Negative Participants

The percentage of PD-L1 negative participants who experienced an objective response (complete response \[CR\] or partial response \[PR\]), based on investigator assessments according to response evaluation criteria in solid tumors 1.1 (RECIST1.1). A CR was defined as the disappearance of all target lesions (TLs) since baseline. Any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10 mm. A PR was defined as at least a 30% decrease in the sum of the diameters of TLs, taking as reference the baseline sum of diameters. PD-L1 negative was defined as \<25% of tumor cells with membrane staining for PD-L1 at any intensity.

Time frame:
September 2015 to September 2018 (36 months)
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) in PD-L1 Negative Participants
Percentage of participantsDurvalumab + TremelimumabDurvalumabStandard of Care (SoC)
Objective Response Rate (ORR) in PD-L1 Negative Participants17.7 (12.4 to 24.2)14.0 (9.1 to 20.0)15.3 (10.3 to 21.4)
Statistical analysis
  • Durvalumab + Tremelimumab vs Durvalumab · Odds ratio (or): 1.33 · 95% CI 0.74 to 2.39
SecondaryTime to Deterioration in European Organisation for Research and Treatment of Cancer 30-item Core Quality of Life Questionnaire, Version 3 (EORTC QLQ-C30)

The EORTC QLQ-C30 consists of 30 questions that can be combined to produce functional scales (e.g. physical), symptom scales (e.g. fatigue), and a global measure of health status. Each of the scales are measured from 0 to 100. Deterioration was defined as a 10-point decrease from baseline in a functioning or global health status/ quality of life score or a 10-point increase from baseline in a symptom score.

Time frame:
September 2015 to September 2018 (36 months)
Reported as:
Median · Months
Time to Deterioration in European Organisation for Research and Treatment of Cancer 30-item Core Quality of Life Questionnaire, Version 3 (EORTC QLQ-C30)
MonthsDurvalumab + TremelimumabDurvalumabStandard of Care (SoC)
Function - Physical2.0 (1.9 to 3.2)2.2 (1.9 to 3.5)3.7 (2.3 to 4.6)
Symptom - Fatigue1.8 (1.3 to 1.9)1.4 (1.0 to 1.9)1.9 (1.6 to 2.6)
Global health status/QoL1.9 (1.8 to 2.7)2.8 (1.9 to 3.8)3.5 (2.9 to 4.0)
SecondaryTime to Deterioration for European Organisation for Research and Treatment of Cancer 35-item Head and Neck Quality of Life Questionnaire (EORTC QLQ-H&N35)

The EORTC QLQ-H\&N35 comprises of 35 questions to assess head and neck cancer symptoms (e.g. pain, swallowing). Deterioration was defined as a 10-point increase from baseline in the symptom score.

Time frame:
September 2015 to September 2018 (36 months)
Reported as:
Median · Months
Time to Deterioration for European Organisation for Research and Treatment of Cancer 35-item Head and Neck Quality of Life Questionnaire (EORTC QLQ-H&N35)
MonthsDurvalumab + TremelimumabDurvalumabStandard of Care (SoC)
Pain (Mouth/ Throat)2.9 (2.4 to 3.8)2.8 (2.6 to 3.7)3.4 (2.7 to 4.0)
Swallowing2.6 (1.9 to 3.6)2.8 (1.9 to 3.9)3.7 (2.9 to 4.6)
SecondaryNumber of Participants Reporting One or More Adverse Events (AE)

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. Inclusive of AEs and serious AEs.

Time frame:
First dose to last dose + 90 days or data cut off (up to 36 months)
Reported as:
Count of participants · Participants
Number of Participants Reporting One or More Adverse Events (AE)
ParticipantsDurvalumab + TremelimumabDurvalumabStandard of Care (SoC)
Number of Participants Reporting One or More Adverse Events (AE)232214229

Adverse events

Collected over First dose to last dose + 90 days or data cut off (maximum exposure 32 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Durvalumab + Tremelimumab206/247 (83.4%)79/246 (32.1%)203/246 (82.5%)
Durvalumab186/240 (77.5%)69/237 (29.1%)180/237 (75.9%)
Standard of Care (SoC)199/249 (79.9%)61/240 (25.4%)207/240 (86.3%)
Most frequent serious events
Showing 10 of 163
Most frequent serious events
EventDurvalumab + TremelimumabDurvalumabStandard of Care (SoC)
PneumoniaInfections and infestations9/2468/2379/240
Tumour haemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps)7/2464/2372/240
Pneumonia aspirationRespiratory, thoracic and mediastinal disorders3/2465/2372/240
AnaemiaBlood and lymphatic system disorders5/2460/2371/240
General physical health deteriorationGeneral disorders0/2464/2371/240
HypercalcaemiaMetabolism and nutrition disorders2/2464/2372/240
SepsisInfections and infestations3/2460/2374/240
Pulmonary embolismRespiratory, thoracic and mediastinal disorders4/2461/2370/240
DysphagiaGastrointestinal disorders4/2461/2371/240
PyrexiaGeneral disorders4/2462/2372/240
Most frequent other events
Showing 10 of 35
Most frequent other events
EventDurvalumab + TremelimumabDurvalumabStandard of Care (SoC)
AnaemiaBlood and lymphatic system disorders55/24647/23756/240
AstheniaGeneral disorders51/24642/23756/240
Decreased appetiteMetabolism and nutrition disorders44/24630/23748/240
NauseaGastrointestinal disorders30/24627/23741/240
FatigueGeneral disorders40/24631/23735/240
DiarrhoeaGastrointestinal disorders38/24624/23732/240
RashSkin and subcutaneous tissue disorders18/24619/23736/240
HypothyroidismEndocrine disorders32/24633/2375/240
ConstipationGastrointestinal disorders33/24633/23729/240
NeutropeniaBlood and lymphatic system disorders11/2464/23732/240

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Durvalumab + TremelimumabDurvalumabStandard of Care (SoC)Total
Mean59.9 ± 9.1459.0 ± 10.0759.5 ± 10.3759.4 ± 9.86
Age, Customized
Age, Customized(Participants)Durvalumab + TremelimumabDurvalumabStandard of Care (SoC)Total
< 65 Years174169171514
>= 65 - < 75 Years635664183
>= 75 Years10151439
Sex: Female, Male
Sex: Female, Male(Participants)Durvalumab + TremelimumabDurvalumabStandard of Care (SoC)Total
Female383842118
Male209202207618
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Durvalumab + TremelimumabDurvalumabStandard of Care (SoC)Total
Hispanic or Latino16151344
Not Hispanic or Latino226223229678
Unknown or Not Reported52714
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Durvalumab + TremelimumabDurvalumabStandard of Care (SoC)Total
Asian333545113
Black Or African American1034
Other45312
White204198189591
Unknown or Not Reported52916
09

Study locations

169 sites
  • Research Site
    Tucson, Arizona 85711, United States
  • Research Site
    Fullerton, California 92835-3825, United States
  • Research Site
    Los Angeles, California 90089, United States
  • Research Site
    Redondo Beach, California 90277, United States
  • Research Site
    Stanford, California 94305, United States
  • Research Site
    Denver, Colorado 80218, United States
  • Research Site
    Newark, Delaware 19713, United States
  • Research Site
    Miami Beach, Florida 33140, United States
  • Research Site
    Orlando, Florida 32806, United States
  • Research Site
    Atlanta, Georgia 30322, United States
  • Research Site
    Evanston, Illinois 60201-1718, United States
  • Research Site
    Lexington, Kentucky 40536, United States
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    Rochester, New York 14621, United States
  • Research Site
    Rochester, New York 14642, United States
  • Research Site
    Winston-Salem, North Carolina 27157, United States
  • Research Site
    Pittsburgh, Pennsylvania 15232, United States
  • Research Site
    Germantown, Tennessee 38138, United States
  • Research Site
    Nashville, Tennessee 37232, United States
  • Research Site
    Dallas, Texas 75230, United States
  • Research Site
    Dallas, Texas 75246, United States
  • Research Site
    McAllen, Texas 78503, United States
  • Research Site
    Norfolk, Virginia 23502, United States
  • Research Site
    Caba, C1426ANZ, Argentina
  • Research Site
    San Miguel de Tucuman, T4000IAK, Argentina
  • Research Site
    Adelaide, 5000, Australia
  • Research Site
    Heidelberg, 3084, Australia
  • Research Site
    Melbourne, 3004, Australia
  • Research Site
    St Leonards, 2065, Australia
  • Research Site
    Woolloongabba, 4102, Australia
  • Research Site
    Brussels, 1090, Belgium
  • Research Site
    Bruxelles, 1200, Belgium
  • Research Site
    Charleroi, 6000, Belgium
  • Research Site
    Kortrijk, 8500, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Namur, 5000, Belgium
  • Research Site
    Barretos, 14784-400, Brazil
  • Research Site
    Curitiba, 81520-060, Brazil
  • Research Site
    Porto Alegre, 90020-090, Brazil
  • Research Site
    Porto Alegre, 90610-000, Brazil
  • Research Site
    Rio de Janeiro, 20231-050, Brazil
  • Research Site
    Santo Andre, 09060-650, Brazil
  • Research Site
    São José do Rio Preto, 15090-000, Brazil
  • Research Site
    São Paulo, 03102-002, Brazil
  • Research Site
    Shumen, 9700, Bulgaria
  • Research Site
    Sofia, 1527, Bulgaria
  • Research Site
    Varna, 9000, Bulgaria
  • Research Site
    Temuco, 4810469, Chile
  • Research Site
    Osijek, 31000, Croatia
  • Research Site
    Zagreb, 10 000, Croatia
  • Research Site
    Olomouc, 775 20, Czechia
  • Research Site
    Zlin, 762 75, Czechia
  • Research Site
    Angers, 49933, France
  • Research Site
    Bordeaux, 33000, France
  • Research Site
    Dijon, 21079, France
  • Research Site
    Le Mans, 72000, France
  • Research Site
    Lyon Cedex 08, 69373, France
  • Research Site
    Montpellier Cedex 5, 34298, France
  • Research Site
    Paris Cedex 5, 75248, France
  • Research Site
    Plerin SUR MER, 22190, France
  • Research Site
    Rouen, 76038, France
  • Research Site
    St Grégoire, 35768, France
  • Research Site
    Strasbourg Cedex, 67085, France
  • Research Site
    Villejuif Cedex, 94805, France
  • Research Site
    Lorient Cedex, 56322, Georgia
  • Research Site
    Berlin, 12200, Germany
  • Research Site
    Essen, 45122, Germany
  • Research Site
    Halle, 06120, Germany
  • Research Site
    Hannover, 30625, Germany
  • Research Site
    Heidelberg, 69120, Germany
  • Research Site
    Leipzig, 04103, Germany
  • Research Site
    München, 81377, Germany
  • Research Site
    Potsdam, 14467, Germany
  • Research Site
    Budapest, 1083, Hungary
  • Research Site
    Budapest, 1122, Hungary
  • Research Site
    Budapest, 1162, Hungary
  • Research Site
    Gyor, 9024, Hungary
  • Research Site
    Kecskemét, 6000, Hungary
  • Research Site
    Haifa, 31096, Israel
  • Research Site
    Jerusalem, 91120, Israel
  • Research Site
    Petach-Tikva, 49100, Israel
  • Research Site
    Tel Aviv, 6423906, Israel
  • Research Site
    Tel Hashomer, 52621, Israel
  • Research Site
    Aosta, 11100, Italy
  • Research Site
    Bologna, 40138, Italy
  • Research Site
    Gallarate, 21013, Italy
  • Research Site
    Legnago, 37045, Italy
  • Research Site
    Milano, 20133, Italy
  • Research Site
    Napoli, 80131, Italy
  • Research Site
    Pavia, 27100, Italy
  • Research Site
    Roma, 00144, Italy
  • Research Site
    Siena, 53100, Italy
  • Research Site
    Chuo-ku, 104-0045, Japan
  • Research Site
    Fukuoka-shi, 811-1395, Japan
  • Research Site
    Hirakata-shi, 573-1191, Japan
  • Research Site
    Isehara-shi, 259-1193, Japan
  • Research Site
    Kashiwa, 277-8577, Japan
  • Research Site
    Kitaadachi-gun, 362-0806, Japan
  • Research Site
    Kobe-shi, 650-0017, Japan
  • Research Site
    Koto-ku, 135-8550, Japan

Showing the first 100 of 169 sites across 24 countries. Choose a country and city above to see the rest.

10

References and documents

Publications

  • Ferris RL, Haddad R, Even C, Tahara M, Dvorkin M, Ciuleanu TE, Clement PM, Mesia R, Kutukova S, Zholudeva L, Daste A, Caballero-Daroqui J, Keam B, Vynnychenko I, Lafond C, Shetty J, Mann H, Fan J, Wildsmith S, Morsli N, Fayette J, Licitra L. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. Ann Oncol. 2020 Jul;31(7):942-950. doi: 10.1016/j.annonc.2020.04.001. Epub 2020 Apr 12. PubMed 32294530 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2015 to primary completion in Sep 2018, 36 months.

Results were first posted in Oct 2019, 1 year after primary completion.

Of 66 phase 3 interventional studies under Head and Neck Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 100. This study's 36 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2015
First posted
Feb 24, 2015
StartActual
Sep 9, 2015
Primary completionActual
Sep 10, 2018
CompletionActual
Nov 13, 2020
Results first posted
Oct 3, 2019
Last update
Feb 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02369874
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 24, 2015
Start date
Sep 9, 2015
Primary completion
Sep 10, 2018
Completion
Nov 13, 2020
Results posted
Oct 3, 2019
Last update
Feb 10, 2021

Study contacts

Nassim Morsli, MD
study director · Medical Director AstraZeneca

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Durvalumab · Tremelimumab

Start the discussion